Dermata Therapeutics posts Q1 GAAP EPS of -$0.48
Dermata Therapeutics reported a Q1 GAAP EPS of -$0.48, beating expectations by $0.05.
The company’s cash and cash equivalents decreased to $6.9 million as of March 31, 2026, from $7.5 million as of December 31, 2025.
This decrease of $0.6 million reflects the company’s cash flow for the period.